LncRNA CADM1-AS1 serves as a new prognostic biomarker for gastric cancer.

OBJECTIVE

To investigate the expression of the long non-coding RNA CADM1-AS1 (lncRNA CADM1-AS1) in gastric cancer and its clinical significance.

PATIENTS AND METHODS

The real time fluorescence quantitative polymerase chain reaction (qRT-PCR) was performed to detect the expression difference of lncRNA CADM1-AS1 between gastric cancer and its adjacent normal tissues. Then, the correlation between the expression of CADM1-AS1 in gastric cancer and the clinicopathological characteristics was analyzed by the Chi-square test. Moreover, the potential of lncRNA CADM1-AS1 in predicting the prognosis of patients with GC after the operation was assessed by the Log-rank test and the Cox's proportional hazards regression model.

RESULTS

The expression of lncRNA CADM1-AS1 was significantly decreased in tumor tissues. According to the mean expression of lncRNA CADM1-AS1, the patients were divided into a high expression group and a low expression group, and the expression of lncRNA CADM1-AS1 in gastric cancer was significantly correlated with tumor differentiation, N stage, M stage, and TNM stage. Moreover, the gastric cancer patients with higher expression of lncRNA CADM1-AS1 had a statistically better overall survival (OS) time and progression-free survival (PFS) time. In univariate analyses and multivariate analyses, the expression of lncRNA CADM1-AS1 was an independent prognosis index of patients with gastric cancer.

CONCLUSIONS

LncRNA CADM1-AS1 might be a new prognostic biomarker for gastric cancer.